NewGenIvf Group Limited (NASDAQ:NIVF) Short Interest Update

Posted by George Bondi on Aug 12th, 2026

NewGenIvf Group Limited (NASDAQ:NIVF – Get Free Report) saw a large drop in short interest in the month of July. As of July 31st, there was short interest totaling 8,932 shares, a drop of 86.7% from the July 15th total of 67,374 shares. Currently, 0.2% of the company’s shares are sold short. Based on an average daily volume of 245,249 shares, the days-to-cover ratio is presently 0.0 days.

Insider Buying and Selling

In other NewGenIvf Group news, major shareholder Financial Lp Hrt purchased 45,847 shares of the stock in a transaction on Friday, May 22nd. The stock was acquired at an average cost of $2.97 per share, with a total value of $136,165.59. Following the completion of the purchase, the insider directly owned 37,295 shares of the company’s stock, valued at approximately $110,766.15. This trade represents a -536.10% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 31.80% of the stock is currently owned by insiders.

NewGenIvf Group Price Performance

NIVF stock traded up $0.01 during trading on Wednesday, hitting $0.53. 56,512 shares of the stock traded hands, compared to its average volume of 876,751. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.98 and a current ratio of 3.12. NewGenIvf Group has a 1 year low of $0.52 and a 1 year high of $513.00. The firm’s 50 day moving average is $1.42 and its two-hundred day moving average is $5.32.

NewGenIvf Group (NASDAQ:NIVF – Get Free Report) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($861.72) earnings per share for the quarter. The firm had revenue of $1.42 million during the quarter. Analysts anticipate that NewGenIvf Group will post 14.22 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on NIVF. Wall Street Zen upgraded NewGenIvf Group to a “hold” rating in a research report on Saturday, July 4th. Weiss Ratings restated a “sell (d)” rating on shares of NewGenIvf Group in a report on Friday, July 24th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, NewGenIvf Group has a consensus rating of “Sell”.

Read Our Latest Stock Report on NewGenIvf Group

NewGenIvf Group Company Profile

(Get Free Report)

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.